Health-related costs in a sample of premenopausal non-diabetic overweight or obese females in Antwerp region: a cost-of-illness analysis

W Hens, D Vissers, L Annemans, J Gielen, L Van Gaal, J Taeymans, N Verhaeghe, W Hens, D Vissers, L Annemans, J Gielen, L Van Gaal, J Taeymans, N Verhaeghe

Abstract

Background: People with overweight or obesity are at increased risk for disease later in life which cause important health costs.The aim of this study was to estimate the health status and the corresponding costs in a sample of females with overweight or obesity which were participating in a Randomized Controlled Trial (RCT) exploring the effect of lifestyle habits changes on ectopic adipose tissue.

Methods: Sixty-two non-diabetic premenopausal females without major comorbidities of overweight and obesity were recruited among patients visiting endocrinologists at the obesity clinic of the University Hospital of Antwerp and the University of Antwerp.A RCT-embedded cost-of-illness approach with societal perspective, based on self-reported questionnaires and cost diaries (3 months recall) was applied to estimate the prevalence of different comorbidities and the related direct and indirect costs in this sample of overweight or obese females. The European Quality-of-Life-5D questionnaire was used to define the health state and the corresponding utility index of the participants.

Results: The average direct health costs and health utilities observed in this sample were comparable with the general Flemish female population. This may partially be explained by the strict inclusion criteria of the RCT (i.e. overweight or obesity without diabetes type 2 or cardiovascular diseases). However, 15% of the participants had five or more comorbidities resulting in higher average costs and lower average health utility as compared to the general population, only 3 participants were diagnozed with the metabolic syndrome. In this subsample productivity was low due to high average absenteeism, yielding important total costs for the society.

Conclusion: Secondary prevention to avoid health deterioration in overweight or obese females without major comorbidies is needed to contain health care costs.

Trial registration: ClinicalTrials.gov: NCT02831621, approval of the ethics committee of the University Hospital of Antwerp (number: 14/17/205 -ref: 7543075363).

Keywords: Cost-of-illness analysis; Obesity; Overweight; Public health.

Conflict of interest statement

This study was approved by the ethics committee of the University Hospital of Antwerp (number: 14/17/205 -ref: 7543075363). All participants gave written informed consent before data collection began.Not applicable.The authors declare that they have no competing interests.Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

Fig. 1
Fig. 1
Components of cost analysis

References

    1. Finucane MM, Stevens GA, Cowan MJ, Danaei G, Lin JK, Paciorek CJ, et al. National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participants. Lancet. 2011;377:557–567. doi: 10.1016/S0140-6736(10)62037-5.
    1. Dee A, Kearns K, O'Neill C, Sharp L, Staines A, O'Dwyer V, et al. The direct and indirect costs of both overweight and obesity: a systematic review. BMC Res Notes. 2014;7:242. doi: 10.1186/1756-0500-7-242.
    1. Drieskens S. Voedingsgewoonten. In: Gisle L, Demarest S, editors. Gezondheidsenquête 2013 Rapport 2. Brussel: Gezondheidsgedrag en leefstijl WIV-ISP; 2014.
    1. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998;15:539–553. doi: 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>;2-S.
    1. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) JAMA. 2001;285:2486–2497. doi: 10.1001/jama.285.19.2486.
    1. Moreira GC, Cipullo JP, Ciorlia LA, Cesarino CB, Vilela-Martin JF. Prevalence of metabolic syndrome: association with risk factors and cardiovascular complications in an urban population. PLoS One. 2014;9:e105056. doi: 10.1371/journal.pone.0105056.
    1. Boudreau DM, Malone DC, Raebel MA, Fishman PA, Nichols GA, Feldstein AC, et al. Health care utilization and costs by metabolic syndrome risk factors. Metab Syndr Relat Disord. 2009;7:305–314. doi: 10.1089/met.2008.0070.
    1. Konnopka A, Bodemann M, Konig HH. Health burden and costs of obesity and overweight in Germany. Eur J Health Econ. 2011;12:345–352. doi: 10.1007/s10198-010-0242-6.
    1. Cawley J, Rizzo JA, Haas K. Occupation-specific absenteeism costs associated with obesity and morbid obesity. J Occup Environ Med. 2007;49:1317–1324. doi: 10.1097/JOM.0b013e31815b56a0.
    1. World Health Organisation. Regional Office for Europe. Highlights on health in Belgium 2004. Copenhagen: World Health Organisation. . Accessed 2/7/2017
    1. Rice DP. Cost of illness studies: what is good about them? Inj Prev. 2000;6:177–179. doi: 10.1136/ip.6.3.177.
    1. Changik J. Cost-of-illness studies: concepts, scopes, and methods.Clin Mol Hepatol. 2014;20(4):327–337.
    1. Moore TJ, Caulkins JP. How cost-of-illness studies can be made more useful for illicit drug policy analysis. Appl Health Econ Health Policy. 2006;5:75–85. doi: 10.2165/00148365-200605020-00002.
    1. Hens W, Vissers D, Annemans L, Gielen J, Van Gaal L, Taeymans J. Cost-effectiveness analysis of exercise in addition to diet on the reduction of ectopic fat in women with overweight study protocol for a randomised controlled trial. Physioscience. 2017;13:80-87.
    1. De Jonghe E. De maatschappelijke kosten van obesitas in Vlaanderen : een pilootstudie met focus op de directe gezondheidskosten. Universiteit Gent, Faculteit geneeskunde en gezondheidswetenschappen; 2009. .
    1. Van Hout B, Janssen MF, Feng YS, Kohlmann T, Busschbach J, Golicki D, et al. Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets. Value Health. 2012;15:708–715. doi: 10.1016/j.jval.2012.02.008.
    1. Rijksinstituut voor Ziekte- en Invaliditeitsverzekering (R.I.Z.I.V.). Omzendbrief VI nr 2016/390 Tarieven; geneesheren - medische verstrekkingen. . Accessed 2/7/2017.
    1. Rijksinstituut voor Ziekte- en Invaliditeitsverzekering (R.I.Z.I.V.).Omzendbrief aan de kinesitherapeuten 2017/01, Tarieven; Kinesitherapeuten. . Accessed 2/7/2017.
    1. Rijksinstituut voor Ziekte- en Invaliditeitsverzekering (R.I.Z.I.V.). Omzendbrief VI nr 2016/376, Tarieven; Revalidatieverstrekkingen. . Accessed 2/7/2017.
    1. Rijksinstituut voor Ziekte- en Invaliditeitsverzekering (R.I.Z.I.V.). Omzendbrief VI nr 2017/123 van 26 april 2017: tarieven kinesitherapeuten. Accessed 2/7/2017. .
    1. Belgisch Centrum voor Farmacotherapeutische Informatie (BCFI). Gecommentarieerd Geneesmiddelenrepertorium. . Accessed 2/7/2017.
    1. Securex. Absenteïsme in 2013 Versnelde stijging lange afwezigheden maakt re-integratiebeleid noodzakelijk. . Accessed 2/7/2017.
    1. Van der Heyden J, Charafeddine R. Gezondheidsenquête 2013. Rapport 1: Gezondheid en Welzijn, Wetenschappelijk Instituut Volksgezondheid. 2014. . Accessed 2/7/2017.
    1. Fontaine KR, Barofsky I. Obesity and health-related quality of life. Obes Rev. 2001;2:173–182. doi: 10.1046/j.1467-789x.2001.00032.x.
    1. Sullivan M, Karlsson J, Sjostrom L, Backman L, Bengtsson C, Bouchard C, et al. Swedish obese subjects (SOS)--an intervention study of obesity. Baseline evaluation of health and psychosocial functioning in the first 1743 subjects examined. Int J Obes Relat Metab Disord. 1993;17:503–512.
    1. Raebel MA, Malone DC, Conner DA, Xu S, Porter JA, Lanty FA. Health services use and health care costs of obese and nonobese individuals. Arch Intern Med. 2004;164:2135–2140. doi: 10.1001/archinte.164.19.2135.
    1. de Oliveira ML, Santos LM, da Silva EN. Direct healthcare cost of obesity in Brazil: an application of the cost-of-illness method from the perspective of the public health system in 2011. PLoS One. 2015;10:e0121160. doi: 10.1371/journal.pone.0121160.
    1. Lette M, Bemelmans WJ, Breda J, Slobbe LC, Dias J, Boshuizen HC. Health care costs attributable to overweight calculated in a standardized way for three European countries. Eur J Health Econ. 2016;17:61–69. doi: 10.1007/s10198-014-0655-8.
    1. Rudisill C, Charlton J, Booth HP, Gulliford MC. Are healthcare costs from obesity associated with body mass index, comorbidity or depression? Cohort study using electronic health records. Clin Obes. 2016;6:225–231. doi: 10.1111/cob.12144.
    1. Seidell JC. Societal and personal costs of obesity. Exp Clin Endocrinol Diabetes. 1998;106(Suppl 2):7–9.
    1. Siderowf A, Ravina B, Glick HA. Preference-based quality-of-life in patients with Parkinson's disease. Neurology. 2002;59:103–108. doi: 10.1212/WNL.59.1.103.
    1. Wolfe F, Hawley DJ. Measurement of the quality of life in rheumatic disorders using the EuroQol. Br J Rheumatol. 1997;36:786–793. doi: 10.1093/rheumatology/36.7.786.
    1. Hamer M, Stamatakis E. Metabolically healthy obesity and risk of all-cause and cardiovascular disease mortality. J Clin Endocrinol Metab. 2012;97:2482–2488. doi: 10.1210/jc.2011-3475.
    1. Ul-Haq Z, Mackay DF, Fenwick E, Pell JP. Impact of metabolic comorbidity on the association between body mass index and health-related quality of life: a Scotland-wide cross-sectional study of 5,608 participants. BMC Public Health. 2012;12:143. doi: 10.1186/1471-2458-12-143.
    1. Bell JA, Kivimaki M, Hamer M. Metabolically healthy obesity and risk of incident type 2 diabetes: a meta-analysis of prospective cohort studies. Obes Rev. 2014;15:504–515. doi: 10.1111/obr.12157.
    1. Chang Y, Kim BK, Yun KE, Cho J, Zhang Y, Rampal S, et al. Metabolically-healthy obesity and coronary artery calcification. J Am Coll Cardiol. 2014;63:2679–2686. doi: 10.1016/j.jacc.2014.03.042.
    1. Tunceli K, Li K, Williams LK. Long-term effects of obesity on employment and work limitations among U.S. adults, 1986 to 1999. Obesity (Silver Spring) 2006;14:1637–1646. doi: 10.1038/oby.2006.188.
    1. Everson SA, Maty SC, Lynch JW, Kaplan GA. Epidemiologic evidence for the relation between socioeconomic status and depression, obesity, and diabetes. J Psychosom Res. 2002;53:891–895. doi: 10.1016/S0022-3999(02)00303-3.
    1. Allender S, Rayner M. The burden of overweight and obesity-related ill health in the UK. Obes Rev. 2007;8:467–473. doi: 10.1111/j.1467-789X.2007.00394.x.
    1. Anis AH, Zhang W, Bansback N, Guh DP, Amarsi Z, Birmingham CL. Obesity and overweight in Canada: an updated cost-of-illness study. Obes Rev. 2010;11:31–40. doi: 10.1111/j.1467-789X.2009.00579.x.
    1. Kang JH, Jeong BG, Cho YG, Song HR, Kim KA. Socioeconomic costs of overweight and obesity in Korean adults. J Korean Med Sci. 2011;26:1533–1540. doi: 10.3346/jkms.2011.26.12.1533.
    1. Tsai AG, Williamson DF, Glick HA. Direct medical cost of overweight and obesity in the USA: a quantitative systematic review. Obes Rev. 2011;12:50–61. doi: 10.1111/j.1467-789X.2009.00708.x.
    1. Zhao W, Zhai Y, Hu J, Wang J, Yang Z, Kong L, et al. Economic burden of obesity-related chronic diseases in mainland China. Obes Rev. 2008;9(Suppl 1):62–67. doi: 10.1111/j.1467-789X.2007.00440.x.
    1. Goossens ME, Rutten-van Molken MP, Vlaeyen JW, van der Linden SM. The cost diary: a method to measure direct and indirect costs in cost-effectiveness research. J Clin Epidemiol. 2000;53:688–695. doi: 10.1016/S0895-4356(99)00177-8.
    1. Rosch M, Leidl R, Tirpitz C, Reinshagen M, Adler G, Konig HH. Cost measurement based on a cost diary in patients with inflammatory bowel disease. Z Gastroenterol. 2002;40:217–228. doi: 10.1055/s-2002-25153.
    1. Effertz T, Engel S, Verheyen F, Linder R. The costs and consequences of obesity in Germany: a new approach from a prevalence and life-cycle perspective. Eur J Health Econ. 2016;17:1141–1158. doi: 10.1007/s10198-015-0751-4.
    1. Single E. Estimating the costs of substance abuse: implications to the estimation of the costs and benefits of gambling. J Gambl Stud. 2003;19:215–233. doi: 10.1023/A:1023633432745.
    1. Drummond M. Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press; 2015.
    1. Desaigues B, Hutchison M, Chilton S, Metcalf H, Hunt A, Ortiz R, et al. Université Paris. 2006. Final report on the monetary valuation of mortality and morbidity risks from air pollution.
    1. Verhaeghe N, Lievens D, Annemans L, Vander Laenen F, Putman K. The health-related social costs of alcohol in Belgium. BMC Public Health. 2017;17:958. doi: 10.1186/s12889-017-4974-4.
    1. Johnston K, Buxton MJ, Jones DR, Fitzpatrick R. Assessing the costs of healthcare technologies in clinical trials. Health Technol Assess. 1999;3:1–76.
    1. Thorn JC, Coast J, Cohen D, Hollingworth W, Knapp M, Noble SM, et al. Resource-use measurement based on patient recall: issues and challenges for economic evaluation. Appl Health Econ Health Policy. 2013;11:155–161. doi: 10.1007/s40258-013-0022-4.
    1. Pitayatienanan P, Butchon R, Yothasamut J, Aekplakorn W, Teerawattananon Y, Suksomboon N, et al. Economic costs of obesity in Thailand: a retrospective cost-of-illness study. BMC Health Serv Res. 2014;14:146. doi: 10.1186/1472-6963-14-146.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren